Clinical Trial Update: Etirinotecan Pegol (NKTR-102) in NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial of Etirinotecan Pegol (NKTR-102) in metastatic and recurrent non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Etirinotecan Pegol (etirinotecan pegol)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-04-03